State of the Science Summit on Hematologic Malignancies | Conference

Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies

April 30th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

Dr. Ghosh on PET-Adapted Therapy in Patients With Hodgkin Lymphoma

April 28th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.

Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

April 28th 2018

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Dr. Ai on Single-Agent and Combination Therapy in Patients With MDS

April 27th 2018

Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Dr. Jacobs on the Use of Ibrutinib in High-Risk Patients With CLL

April 27th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

Optimal Combinations, Sequences Being Explored in Multiple Myeloma

November 7th 2017

Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.

Dr. Mikhail on Ongoing Clinical Trials for Patients With Myeloma

November 7th 2017

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma

November 3rd 2017

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

Dr. Stadtmauer on Current Challenges With Multiple Myeloma

November 3rd 2017

Dr. Perl on the Outlook of FLT3 Inhibitors for AML

November 3rd 2017

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs

October 31st 2017

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Dr. Frankfurt on the Future of AML Treatments

October 30th 2017

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Novel Agents Show Impressive Activity in Hodgkin Lymphoma

October 28th 2017

Jane N. Winter, MD, discusses immunotherapy in the treatment of patients with Hodgkin lymphoma.

Expert Sheds Light on Role of Combinations, Transplant in Myeloma

October 27th 2017

Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.

Dr. Rosko on Treatment for Elderly Patients With Multiple Myeloma

October 27th 2017

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Emerging Treatments Show Promise in Myelofibrosis

October 27th 2017

Alice Mims, MD, provides updates on the field of myeloproliferative neoplasms, with a focus on myelofibrosis.

Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma

October 26th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

Dr. Mehta Discusses Combinations in Multiple Myeloma

October 26th 2017

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Dr. Mitchell on Clinical Trials Exploring Medical Marijuana for Patients With Cancer

October 25th 2017

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.